BioSight
Companies
Inventiva S.A. logo

IVA

NASDAQDAIX, I0
Inventiva S.A.

Inventiva S.A. is a clinical-stage biopharmaceutical company developing small molecule therapies across hepatology, fibrosis, and rare diseases, with lanifibranor as its lead program in development for liver disease indications and odiparcil being developed through a collaboration with Biossil. The company has established licensing agreements with Chia Tai Tianqing Pharmaceutical Group and Hepalys Pharma for clinical development and commercialization of its pipeline candidates.

Price history not yet available for IVA.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar